Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;18(10):61.
doi: 10.1007/s11926-016-0609-5.

Infections With Biologics in Rheumatoid Arthritis and Related Conditions: A Scoping Review of Serious or Hospitalized Infections in Observational Studies

Affiliations
Review

Infections With Biologics in Rheumatoid Arthritis and Related Conditions: A Scoping Review of Serious or Hospitalized Infections in Observational Studies

Jasvinder A Singh. Curr Rheumatol Rep. .

Abstract

Biologic use is a major advance in the treatment of several autoimmune conditions, including rheumatoid arthritis. In this review, we summarize key studies of serious/hospitalized infections in rheumatoid arthritis (RA). RA is a risk factor for infections. High RA disease activity is associated with higher risk of serious infection. The risk of serious infections with tumor necrosis factor inhibitor (TNFi) biologics is increased in the first 6 months of initiating therapy, and this risk was higher compared to the use of traditional disease-modifying anti-rheumatic drugs (DMARDs). Emerging data also suggest that biologics may differ from each other regarding the risk of serious or hospitalized infections. Past history of serious infections, glucocorticoid dose, and older age were other important predictors of risk of serious infections in patients treated with biologics.

Keywords: Abatacept; Adalimumab; Biologics; Certolizumab pegol; Etanercept; Golimumab; Hospitalized infection; Infection; Infliximab; Non-TNF biologic; Rituximab; Serious infection; TNFi; Tocilizumab; Tumor-necrosis factor inhibitors.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Arthritis Rheumatol. 2016 Jan;68(1):56-66 - PubMed
    1. Curr Rheumatol Rep. 1999 Dec;1(2):157-63 - PubMed
    1. Lancet. 2015 Jul 18;386(9990):258-65 - PubMed
    1. Scand J Rheumatol. 2005 Sep-Oct;34(5):333-41 - PubMed
    1. J Rheumatol. 2008 Mar;35(3):387-93 - PubMed

MeSH terms

Feedback